PB1903: TRIAL IN PROGRESS: A MULTICENTER, OPEN-LABEL, PHASE IB/II STUDY TO DETERMINE THE DOSE AND SAFETY OF ASCIMINIB IN PEDIATRIC PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP)

Hijiya, N., Kapoor, S., Hoch, M., Descamps, L., Bayar, M. A., & Ramscar, N. (2022). PB1903: TRIAL IN PROGRESS: A MULTICENTER, OPEN-LABEL, PHASE IB/II STUDY TO DETERMINE THE DOSE AND SAFETY OF ASCIMINIB IN PEDIATRIC PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP). HemaSphere, 6, 1782–1783. https://doi.org/10.1097/01.hs9.0000850464.45271.b3

Authors:

N. Hijiya

S. Kapoor

M. Hoch

L. Descamps

M. A. Bayar

N. Ramscar

Affiliated Authors:

N. Hijiya

Subjects:

Efficacy and Resistance in CML Treatment (OpenAlex Topic)

Genomic Aberrations and Treatment of Chronic Lymphocytic Leukemia (OpenAlex Topic)